As observed in cell culture models, monitoring the expression of ERRα by immunohistochemical staining and immunoblotting revealed a significant decrease of ERRα expression on acute lapatinib treatment compared with the control treatment arm, and an increase at end point in ERBB2-dependent tumours that have relapsed (Fig. 2h,i). The gene discussed is ERBB2; the disease is neoplasm.